{"product_id":"anticancer-therapeutics-9781118622124","title":"Anticancer Therapeutics","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cp\u003e\u003cb\u003eAn integrated presentation of the basic science and clinical applications of anticancer agents\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eAimed at both undergraduate and postgraduate readers, this unique text provides readers with a fully-integrated presentation of all aspects of the science of anticancer drugs, including their chemistry, pharmacology, and clinical applications.\u003c\/p\u003e \u003cp\u003eAfter heart disease, cancer is the number one killer worldwide, and the tumor microenvironment is forever changing, creating an ever-greater demand for safer, more effective anticancer agents. In response to that demand, the $100 billion cancer drug market continues to grow, with our increased understanding of cancer leading to new drugs being used clinically almost every year.\u003c\/p\u003e \u003cp\u003e\u003ci\u003eAnticancer Therapeutics \u003c\/i\u003eis divided into three sections. Section 1 is an introduction to cancer and therapeutics, and covers the etiology and cellular and molecular basis of cancer. In Section 2, the authors focus on the anticancer agents  the\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e\u003c\/p\u003e\u003cp\u003ePreface xi\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection 1: Introduction 1\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e1.1 The Global Burden of Cancer 3\u003c\/p\u003e \u003cp\u003eReferences 11\u003c\/p\u003e \u003cp\u003e1.2 Cancer Staging and Classification 13\u003c\/p\u003e \u003cp\u003e1.2.1 Benign Tumour (or neoplasm) 13\u003c\/p\u003e \u003cp\u003e1.2.2 Malignant Tumour (or cancer) 14\u003c\/p\u003e \u003cp\u003e1.2.3 Tumour Nomenclature and Classification 14\u003c\/p\u003e \u003cp\u003e1.2.4 Cellular Differentiation and Tumour Grade 21\u003c\/p\u003e \u003cp\u003e1.2.5 Tumour Invasion and Metastasis 24\u003c\/p\u003e \u003cp\u003e1.2.6 Clinical Staging of Cancer 26\u003c\/p\u003e \u003cp\u003eReferences 36\u003c\/p\u003e \u003cp\u003e1.3 Cellular and Molecular Basis of Cancer 39\u003c\/p\u003e \u003cp\u003e1.3.1 Oncogenes 40\u003c\/p\u003e \u003cp\u003e1.3.2 Tumour Suppressor Genes 45\u003c\/p\u003e \u003cp\u003e1.3.3 Role of Epigenetics and Gene Promoter Regulation in Tumourigenesis 49\u003c\/p\u003e \u003cp\u003e1.3.4 Multistage Tumourigenesis 53\u003c\/p\u003e \u003cp\u003e1.3.5 Oncogene Addiction 54\u003c\/p\u003e \u003cp\u003e1.3.6 Hallmarks of Cancer 55\u003c\/p\u003e \u003cp\u003e1.3.7 Principles of Cancer Treatment 73\u003c\/p\u003e \u003cp\u003eReferences 77\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection 2: The Anticancer Agents 81\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e2.1 Agents Which Act Directly on DNA 83\u003c\/p\u003e \u003cp\u003e2.1.1 Nitrogen Mustards and Nitrosoureas 83\u003c\/p\u003e \u003cp\u003eReferences 96\u003c\/p\u003e \u003cp\u003e2.1.2 Temozolomide 98\u003c\/p\u003e \u003cp\u003eReferences 106\u003c\/p\u003e \u003cp\u003e2.1.3 Platinum]containing Agents 108\u003c\/p\u003e \u003cp\u003eReferences 118\u003c\/p\u003e \u003cp\u003e2.1.4 Gemcitabine 120\u003c\/p\u003e \u003cp\u003eReferences 128\u003c\/p\u003e \u003cp\u003e2.1.5 Camptothecin and Its Analogues 128\u003c\/p\u003e \u003cp\u003eReferences 139\u003c\/p\u003e \u003cp\u003e2.1.6 Podophyllotoxins 141\u003c\/p\u003e \u003cp\u003eReferences 150\u003c\/p\u003e \u003cp\u003e2.1.7 Anthracyclines 151\u003c\/p\u003e \u003cp\u003eReferences 160\u003c\/p\u003e \u003cp\u003e2.1.8 Epigenetic Targeting Agents 162\u003c\/p\u003e \u003cp\u003eReferences 177\u003c\/p\u003e \u003cp\u003e2.2 Antimetabolites 181\u003c\/p\u003e \u003cp\u003e2.2.1 Cytarabine 181\u003c\/p\u003e \u003cp\u003eReferences 183\u003c\/p\u003e \u003cp\u003e2.2.2 Methotrexate 184\u003c\/p\u003e \u003cp\u003eReferences 195\u003c\/p\u003e \u003cp\u003e2.2.3 5]Fluorouracil 196\u003c\/p\u003e \u003cp\u003eReferences 205\u003c\/p\u003e \u003cp\u003e2.2.4 6]Mercaptopurine 206\u003c\/p\u003e \u003cp\u003eReferences 210\u003c\/p\u003e \u003cp\u003e2.3 Antimicrotubule Agents 211\u003c\/p\u003e \u003cp\u003e2.3.1 Taxanes 211\u003c\/p\u003e \u003cp\u003eReferences 224\u003c\/p\u003e \u003cp\u003e2.3.2 Vinca Alkaloids 225\u003c\/p\u003e \u003cp\u003eReferences 231\u003c\/p\u003e \u003cp\u003e2.4 Anti]hormonal Agents 233\u003c\/p\u003e \u003cp\u003e2.4.1 Bicalutamide 233\u003c\/p\u003e \u003cp\u003eReferences 239\u003c\/p\u003e \u003cp\u003e2.4.2 Tamoxifen 240\u003c\/p\u003e \u003cp\u003eReferences 247\u003c\/p\u003e \u003cp\u003e2.4.3 Anastrozole 248\u003c\/p\u003e \u003cp\u003eReferences 254\u003c\/p\u003e \u003cp\u003e2.5 Kinase Inhibitors 257\u003c\/p\u003e \u003cp\u003e2.5.1 Discovery 257\u003c\/p\u003e \u003cp\u003e2.5.2 Synthesis 262\u003c\/p\u003e \u003cp\u003e2.5.3 Mode of Action 267\u003c\/p\u003e \u003cp\u003e2.5.4 Mechanism of Resistance 268\u003c\/p\u003e \u003cp\u003e2.5.5 Adverse Drug Reactions 268\u003c\/p\u003e \u003cp\u003eReferences 271\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection 3: The Cancers 275\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e3.1 Breast Cancer 277\u003c\/p\u003e \u003cp\u003eKey points 277\u003c\/p\u003e \u003cp\u003e3.1.1 Epidemiology 277\u003c\/p\u003e \u003cp\u003e3.1.2 Presentation 279\u003c\/p\u003e \u003cp\u003e3.1.3 Diagnosis 282\u003c\/p\u003e \u003cp\u003e3.1.4 Staging 283\u003c\/p\u003e \u003cp\u003e3.1.5 Treatments 285\u003c\/p\u003e \u003cp\u003eReferences 289\u003c\/p\u003e \u003cp\u003e3.2 Colorectal Cancer 293\u003c\/p\u003e \u003cp\u003eKey points 293\u003c\/p\u003e \u003cp\u003e3.2.1 Epidemiology 293\u003c\/p\u003e \u003cp\u003e3.2.2 Presentation 294\u003c\/p\u003e \u003cp\u003e3.2.3 Diagnosis 296\u003c\/p\u003e \u003cp\u003e3.2.4 Staging 298\u003c\/p\u003e \u003cp\u003e3.2.5 Treatments 299\u003c\/p\u003e \u003cp\u003eReferences 303\u003c\/p\u003e \u003cp\u003e3.3 Leukaemia 307\u003c\/p\u003e \u003cp\u003eKey points 307\u003c\/p\u003e \u003cp\u003e3.3.1 Epidemiology 307\u003c\/p\u003e \u003cp\u003e3.3.2 Presentation 310\u003c\/p\u003e \u003cp\u003e3.3.3 Diagnosis 311\u003c\/p\u003e \u003cp\u003e3.3.4 Staging 313\u003c\/p\u003e \u003cp\u003e3.3.5 Treatments 314\u003c\/p\u003e \u003cp\u003eReferences 319\u003c\/p\u003e \u003cp\u003e3.4 Lung Cancer 323\u003c\/p\u003e \u003cp\u003eKey points 323\u003c\/p\u003e \u003cp\u003e3.4.1 Epidemiology 323\u003c\/p\u003e \u003cp\u003e3.4.2 Presentation 327\u003c\/p\u003e \u003cp\u003e3.4.3 Diagnosis 327\u003c\/p\u003e \u003cp\u003e3.4.4 Staging 330\u003c\/p\u003e \u003cp\u003e3.4.5 Treatments 330\u003c\/p\u003e \u003cp\u003eReferences 337\u003c\/p\u003e \u003cp\u003e3.5 Oesophageal Cancer 339\u003c\/p\u003e \u003cp\u003eKey points 339\u003c\/p\u003e \u003cp\u003e3.5.1 Epidemiology 339\u003c\/p\u003e \u003cp\u003e3.5.2 Presentation 340\u003c\/p\u003e \u003cp\u003e3.5.3 Diagnosis 341\u003c\/p\u003e \u003cp\u003e3.5.4 Staging 344\u003c\/p\u003e \u003cp\u003e3.5.5 Treatments 346\u003c\/p\u003e \u003cp\u003eReferences 350\u003c\/p\u003e \u003cp\u003e3.6 Ovarian Cancer 353\u003c\/p\u003e \u003cp\u003eKey points 353\u003c\/p\u003e \u003cp\u003e3.6.1 Epidemiology 353\u003c\/p\u003e \u003cp\u003e3.6.2 Presentation 354\u003c\/p\u003e \u003cp\u003e3.6.3 Diagnosis 356\u003c\/p\u003e \u003cp\u003e3.6.4 Staging 357\u003c\/p\u003e \u003cp\u003e3.6.5 Treatments 357\u003c\/p\u003e \u003cp\u003eReferences 363\u003c\/p\u003e \u003cp\u003e3.7 Pancreatic Cancer 367\u003c\/p\u003e \u003cp\u003eKey points 367\u003c\/p\u003e \u003cp\u003e3.7.1 Epidemiology 367\u003c\/p\u003e \u003cp\u003e3.7.2 Presentation 368\u003c\/p\u003e \u003cp\u003e3.7.3 Diagnosis 370\u003c\/p\u003e \u003cp\u003e3.7.4 Staging 371\u003c\/p\u003e \u003cp\u003e3.7.5 Treatments 373\u003c\/p\u003e \u003cp\u003eReferences 375\u003c\/p\u003e \u003cp\u003e3.8 Prostate Cancer 379\u003c\/p\u003e \u003cp\u003eKey points 379\u003c\/p\u003e \u003cp\u003e3.8.1 Epidemiology 379\u003c\/p\u003e \u003cp\u003e3.8.2 Presentation 381\u003c\/p\u003e \u003cp\u003e3.8.3 Diagnosis 382\u003c\/p\u003e \u003cp\u003e3.8.4 Staging 384\u003c\/p\u003e \u003cp\u003e3.8.5 Treatments 387\u003c\/p\u003e \u003cp\u003eReferences 391\u003c\/p\u003e \u003cp\u003e3.9 Skin Cancers 393\u003c\/p\u003e \u003cp\u003eKey points 393\u003c\/p\u003e \u003cp\u003e3.9.1 Epidemiology 393\u003c\/p\u003e \u003cp\u003e3.9.2 Presentation 394\u003c\/p\u003e \u003cp\u003e3.9.3 Diagnosis 395\u003c\/p\u003e \u003cp\u003e3.9.4 Staging 396\u003c\/p\u003e \u003cp\u003e3.9.5 Treatments 399\u003c\/p\u003e \u003cp\u003eReferences 403\u003c\/p\u003e \u003cp\u003e3.10 Testicular Cancer 405\u003c\/p\u003e \u003cp\u003eKey points 405\u003c\/p\u003e \u003cp\u003e3.10.1 Epidemiology 405\u003c\/p\u003e \u003cp\u003e3.10.2 Presentation 407\u003c\/p\u003e \u003cp\u003e3.10.3 Diagnosis 407\u003c\/p\u003e \u003cp\u003e3.10.4 Staging 409\u003c\/p\u003e \u003cp\u003e3.10.5 Treatments 409\u003c\/p\u003e \u003cp\u003eReferences 414\u003c\/p\u003e \u003cp\u003eIndex 417\u003c\/p\u003e","brand":"John Wiley \u0026 Sons Inc","offers":[{"title":"Default Title","offer_id":49406896308567,"sku":"9781118622124","price":144.35,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9781118622124.jpg?v=1730497480","url":"https:\/\/bookcurl.com\/products\/anticancer-therapeutics-9781118622124","provider":"Book Curl","version":"1.0","type":"link"}